Nuvation Bio/$NUVB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nuvation Bio

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Ticker

$NUVB

Primary listing

NYSE

Industry

Pharmaceuticals

Employees

273

ISIN

US67080N1019

Nuvation Bio Metrics

BasicAdvanced
$609M
-
-$2.03
1.37
-

What the Analysts think about Nuvation Bio

Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.

Bulls say / Bears say

Nuvation Bio's submission of a New Drug Application (NDA) to the FDA for taletrectinib in October 2024 positions the company for potential commercialization in the U.S. by mid-2025, which could significantly boost revenue if approved. (beyondspx.com)
The acquisition of AnHeart Therapeutics in April 2024 added new product candidates and revenue streams, contributing to a positive operating cash flow of $53 million in the quarter ended September 30, 2024. (beyondspx.com)
As of September 30, 2024, Nuvation Bio maintained a strong liquidity position with $549.1 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation for ongoing R&D activities. (beyondspx.com)
Nuvation Bio reported a net loss of $53.2 million for the quarter ended March 31, 2025, indicating ongoing financial challenges. (stocktitan.net)
The company's total liabilities increased by 369.6% from 2023 to 2024, raising concerns about its financial health and debt management. (marketbeat.com)
Nuvation Bio's earnings per share (EPS) was -$2.23 as of September 30, 2024, reflecting significant losses per share and potential dilution concerns. (fintel.io)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.

Nuvation Bio Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Nuvation Bio Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NUVB

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs